Here's 80 Billion More Reasons to Buy Novo Nordisk Stock
Novo Nordisk is already developing its next set of weight loss therapies. At least one market research firm is incredibly optimistic about its prospects.
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market
Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources famil...
Novo Nordisk Gains as Ozempic Found To Lower Dementia Rates
American depositary receipts (ADRs) of Novo Nordisk (NVO) rose in intraday trading Friday after the release of an Oxford study that showed the Danish company's Ozempic diabetes drug was linked to l...
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec
Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application ...
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices
Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk can be convinced to cut the U.S. prices of its popular Ozempic and Wegovy used for weight loss by publicly shaming the dru...
Novo Nordisk, Indonesia's Bio Farma sign deal to produce insulin
Danish drugmaker Novo Nordisk has signed a deal with Indonesia's state-owned pharmaceutical company Bio Farma to produce insulin to combat diabetes in the Southeast Asian country, a Bio Farma senio...
Imperial College spin-out Myricx Bio lands £90m of new investment
An Imperial College spin-out has landed £90 million in Series-A funding backed by heavyweight investors, including an offshoot of the British Business Bank (BBB). Myricx Bio, the recipient of this ...
Is It Too Late to Buy Novo Nordisk Stock?
Novo Nordisk's valuation is high, and the U.S. patent for semaglutide expires in early 2026. However, the drugmaker has a promising pipeline that could drive growth for years to come.
Novo Nordisk shares drop as study links drugs to vision loss
Novo Nordisk (NYSE:NVO) shares have dropped by close to 4% this week, shedding more than £350 billion from its market cap, after a study suggested there may be a link between its blockbuster weight...
Novo Nordisk shares shrug off concerns over study linking weight loss drugs to rare eye condition
Blockbuster weight loss drugs such as Wegovy and Ozempic may be associated with a rare eye condition, according to a new study released Wednesday. A Novo Nordisk spokesperson said there were "key m...
Using Ozempic Or Wegovy Could Raise Risk For Rare Form Of Blindness, Study Suggests
People who use Ozempic or Wegovy for treating obesity or Type 2 diabetes may have an increased risk of developing a rare form of blindness, according to a study published Wednesday in the journal J...
Novo Nordisk steps up ad spend to keep the weight-loss crown
Novo Nordisk (NYSE:NVO) appears to be taking a no-holds-barred approach to becoming the number one weight-loss drug in the US after it emerged that an ad for one of its key products was viewed near...
Ozempic craze: Novo Nordisk invests $4.1B in US to expand manufacturing
Novo Nordisk is ramping up the manufacturing capacity of its obesity-related drugs as demand for Wegovy and Ozempic continues to surge. It's pouring $4.1 billion to expand its facility.
Novo Nordisk's Wegovy weight loss drug approved in China
Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management. The approval opens up the blockbuster drug for sale for those with obesit...
Related Companies